Table 2.
The haemodynamic and laboratory parameters of the two study groups
| Variable | Liothyronin | Placebo | Liothyronin vs. placebo | ||||
|---|---|---|---|---|---|---|---|
| (n = 25) | (n = 25) | ||||||
| Before | After | P‐value | Before | After | P‐value | P‐value | |
| HR, b.p.m | 67 ± 25 | 82 ± 21 | 0.52 | 65 ± 14 | 76 ± 16 | 0.76 | 0.64 |
| SBP, mmHg | 125 ± 15 | 123 ± 18 | 0.43 | 117 ± 14 | 112 ± 18 | 0.37 | 0.56 |
| DBP, mmHg | 75 ± 16 | 73 ± 21 | 0.86 | 69 ± 25 | 74 ± 15 | 0.96 | 0.85 |
| MAP, mmHg | 90 ± 8 | 86 ± 11 | 0.54 | 87 ± 12 | 89 ± 9 | 0.84 | 0.73 |
| TSH, mU/L | 3.01 ± 0.94 | 2.90 ± 1.06 | 0.21 | 2.46 ± 1.81 | 2.02 ± 1.08 | 0.73 | 0.35 |
| Free T3, pg/mL | 1.15 ± 0.29 | 2.37 ± 0.84 | <0.001 | 1.24 ± 0.17 | 1.44 ± 0.13 | 0.62 | <0.001 |
| Free T4, pg/mL | 15.33 ± 3.96 | 13.97 ± 3.71 | 0.76 | 14.76 ± 3.14 | 15.53 ± 3.73 | 0.45 | 0.85 |
| NT‐proBNP, ng/dL | 4995.43 ± 1281.39 | 1268.36 ± 847.83 | 0.01 | 5145.06 ± 1368.83 | 3401.50 ± 1846.12 | 0.23 | <0.001 |
| Hs‐CRP, mg/dL | 21.69 ± 11.42 | 9.67 ± 3.56 | 0.02 | 23.54 ± 12.45 | 15.33 ± 9.45 | 0.44 | <0.001 |
| Haemoglobin, g/dL | 12.63 ± 2.00 | 13.39 ± 2.32 | 0.49 | 11.73 ± 2.27 | 12.53 ± 1.69 | 0.19 | 0.85 |
| Uric acid, mg/dL | 6.24 ± 2.96 | 4.91 ± 2.73 | 0.34 | 7.09 ± 2.55 | 5.30 ± 1.37 | 0.29 | 0.03 |
| Creatinine, mg/dL | t1.54 ± 0.77 | 1.52 ± 0.70 | 0.47 | 1.55 ± 0.55 | 1.49 ± 0.43 | 0.76 | 0.63 |
Data are presented as means ± standard deviation.
DBP, diastolic blood pressure; HR, heart rate; Hs‐CRP, high‐sensitivity C‐reactive protein; MAP, mean arterial pressure; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; SBP, systolic blood pressure; TSH; thyroid‐stimulating hormone, T3; triiodothyronine, T4; thyroxin.